Research programme: antiviral therapeutics - SIGA

Drug Profile

Research programme: antiviral therapeutics - SIGA

Alternative Names: ST-148; ST-193; ST-294; ST-383; ST-610; ST-669

Latest Information Update: 23 Sep 2014

Price : $50

At a glance

  • Originator SIGA Technologies
  • Class Benzimidazoles; Small molecules
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Bunyavirus infections; Dengue; Ebola virus infections; Junin virus infections; Lassa fever; Marburg virus disease; Viral infections

Most Recent Events

  • 24 Aug 2011 SIGA technologies receives grant from National Institutes of Health (NIH) for antiviral drug development in Lassa fever and other haemorrhagic fevers of Arenavirus origin
  • 25 Feb 2010 SIGA Technologies receives funding from the US Department of Defense for ST 669 development in Viral infections
  • 25 Feb 2010 Preclinical trials in Viral infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top